Magnetic Resonance Imaging–Transectal Ultrasound Image-fusion Biopsies Accurately Characterize the Index Tumor: Correlation with Step-sectioned Radical Prostatectomy Specimens in 135 Patients

Baco, Eduard; Ukimura, Osamu; Rud, Erik; Vlatkovic, Ljiljana; Svindland, Aud; Aron, Manju; Palmer, Suzanne; Matsugasumi, Toru; Marien, Arnaud; Bernhard, Jean-Christophe; Rewcastle, John C.; Eggesbø, Heidi B.; Gill, Inderbir S.

doi:10.1016/j.eururo.2014.08.077

Cited by 214 publications

(132 citation statements)

References 30 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Some authors biopsize all PI-RADS score 3 lesions [44] leading to increased number of unnecessary biopsies, on the other hand, others have demonstrated that PI-RADS score 3 lesions are associated with low likelihood of clinically sPCa, concluding that these lesions should not be sampled but monitored only. [45] Several studies [25,29] have demonstrated the adequacy of MRI lesion volume estimation compared to histopathological tumor volume. According to the Epstein criteria [46] , the presence of sPCa should be predicted by lesion volume measurement, using a cut-off value of 0.5 cm 3 .…”

Section: Biparametric Mri Volume Calculation For the Management Of Scmentioning

confidence: 99%

“…[30] Several authors have also reported a good correlation between radiologic estimation of the lesion volume and histology of the tumor volüme. [19,25,30] A potential of bpMRI is represented by the management (biopsy or clinical surveillance) of the score 3 lesions through the calculation of their volume (cut-off of 0.5 cm 3 ) which is consequently a simplification of PI-RADS v2. In this article we review the bpMRI of the prostate and its performance in the detection, localization and management of PCa.…”

Section: Introductionmentioning

confidence: 99%

“…[18] Biparametric MRI (bpMRI), including T2W and DW MRI series, has been recently proposed to overcome these limitations and to offer a more appropriate management of PCa. [21][22][23][24][25][26][27][28] The benefits of bpMRI are represented by the reduced costs, shorter time required to complete the study, and the no-use of gadolinium. In addition, bpMRI provides similar results to those of mpMRI for the detection and localization of PCa.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biparametric MRI of the prostate

Scialpi

D’Andrea

Martorana

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Biparametric Magnetic Resonance Imaging (bpMRI) of the prostate combining both morphologic T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) is emerging as an alternative to multiparametric MRI (mpMRI) to detect, to localize and to guide prostatic targeted biopsy in patients with suspicious prostate cancer (PCa). BpMRI overcomes some limitations of mpMRI such as the costs, the time required to perform the study, the use of gadolinium-based contrast agents and the lack of a guidance for management of score 3 lesions equivocal for significant PCa. In our experience the optimal and similar clinical results of the bpMRI in comparison to mpMRI are essentially related to the DWI that we consider the dominant sequence for detection suspicious PCa both in transition and in peripheral zone. In clinical practice, the adoption of bpMRI standardized scoring system, indicating the likelihood to diagnose a clinically significant PCa and establishing the management of each suspicious category (from 1 to 4), could represent the rationale to simplify and to improve the current interpretation of mpMRI based on Prostate Imaging and Reporting Archiving Data System version 2 (PI-RADS v2). In this review article we report and describe the current knowledge about bpMRI in the detection of suspicious PCa and a simplified PI-RADS based on bpMRI for management of each suspicious PCa categories to facilitate the communication between radiologists and urologists.

show abstract

Section: Biparametric Mri Volume Calculation For the Management Of Scmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biparametric MRI of the prostate

Scialpi

D’Andrea

Martorana

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Few studies have correlated the findings of mpMRI and targeted PBx with the final histopathology of the RP specimen [9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography‐fusion biopsy

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo compare multiparametric magnetic resonance imaging (mpMRI) of the prostate and histological findings of both targeted MRI/ultrasonography-fusion prostate biopsy (PBx) and systematic PBx with final histology of the radical prostatectomy (RP) specimen. Patients and MethodsA total of 105 patients with prostate cancer (PCa) histopathologically proven using a combination of fusion Pbx and systematic PBx, who underwent RP, were investigated. All patients had been examined using mpMRI, applying the European Society of Urogenital Radiology criteria. Histological findings from the RP specimen were compared with those from the PBx. Whole-mount RP specimen and mpMRI results were directly compared by a uro-pathologist and a uro-radiologist in step-section analysis. ResultsIn the 105 patients with histopathologically proven PCa by combination of fusion PBx and systematic PBx, the detection rate of PCa was 90% (94/105) in fusion PBx alone and 68% (72/105) in systematic PBx alone (P = 0.001). The combination PBx detected 23 (22%) Gleason score (GS) 6, 69 (66%) GS 7 and 13 (12%) GS ≥8 tumours. Fusion PBx alone detected 25 (26%) GS 6, 57 (61%) GS 7 and 12 (13%) GS ≥8 tumours. Systematic PBx alone detected 17 (24%) GS 6, 49 (68%) GS 7 and 6 (8%) GS ≥8 tumours. . The rates of concordance with regard to GS between the PBx and RP specimen were 63% (n = 65), 54% (n = 56) and 75% (n = 78) in fusion, systematic and combination PBx (fusion and systematic PBx combined), respectively. Upgrading of the GS between PBx and RP specimen occurred in 33% (n = 34), 44% (n = 46) and 18% (n = 19) in fusion, systematic and combination PBx, respectively. c-correlation for detection of any cancer was 0.76 for combination PBx, 0.68 for fusion PBx alone and 0.23 for systematic PBx alone. In all, 84% (n = 88) of index tumours were identified by mpMRI; 86% (n = 91) of index lesions on the mpMRI were proven in the RP specimen. ConclusionsFusion PBx of tumour-suspicious lesions on mpMRI was associated with a higher detection rate of more aggressive PCa and a better tumour prediction in final histopathology than systematic PBx alone; however, combination PBx had the best concordance for the prediction of GS. Furthermore, the additional findings of systematic PBx reflect the multifocality of PCa, therefore, the combination of both biopsy methods would still represent the best approach for the prediction of the final tumour grading in PCa. KeywordsMRI/ultrasound-fusion biopsy, prostate cancer, multiparametric MRI, prostatectomy specimen, systematic biopsy, direct comparison

show abstract

“…mpMRI guided biopsies may miss the index lesions by 5-20%. [63][64][65][66] When fusion biopsies are combined with standard TRUS guided biopsies, the missing rates can be reduced to the minimum. Moreover, it currently lacks resolution to detect tumors with smaller volume and lower Gleason grade.…”

Section: Limitations Of Mpmrimentioning

confidence: 99%

Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions

Demirel

Davis

2018

Turkish Journal of Urology

View full text Add to dashboard Cite

Multiparametric magnetic resonance imaging (mpMRI) has managed to change the paradigms on prostate cancer detection and risk classification. The most clear-cut indication of mpMRI in guidelines is the patients with a history of negative biopsy/increasing prostate-specific antigen (PSA), and presence of additional findings supporting its use in non biopsied patients and active surveillance. mpMRI complements standard clinical exam, PSA measurements, and systematic biopsy, and will miss some tumors that lack enough size or change in tissue density. Use of mpMRI is likely to increase, and further developments in the technique will be important for safe adoption of focal therapy concepts. Here we present a brief summary about mpMRI and its use in detection, risk classification and follow-up of prostate cancer.

show abstract

Magnetic Resonance Imaging–Transectal Ultrasound Image-fusion Biopsies Accurately Characterize the Index Tumor: Correlation with Step-sectioned Radical Prostatectomy Specimens in 135 Patients

Cited by 214 publications

References 30 publications

Biparametric MRI of the prostate

Biparametric MRI of the prostate

Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography‐fusion biopsy

Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions

Contact Info

Product

Resources

About